FDA 483 - Zinoviy T. Benzar, M.D. - December 12, 2025

An FDA inspection of Oasis Clinical Research, LLC in Las Vegas, NV, revealed significant deficiencies in the conduct of clinical investigations. The firm failed to adhere to investigational plans, enrolling subjects who did not meet eligibility criteria and improperly timing sample collections. Additionally, the inspection found inadequate and inaccurate case histories, with issues related to contemporaneous documentation and data alterations.